ITOS — iTeos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $387.11m
- -$144.81m
- $12.60m
- 51
- 24
- 49
- 36
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -22.5 | -38 | 215 | 96.7 | -113 |
Depreciation | |||||
Non-Cash Items | -0.22 | 2.99 | 13.8 | 19.8 | 16.8 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.08 | 9.33 | 284 | -228 | -8.8 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -23.1 | -25.2 | 513 | -111 | -104 |
Capital Expenditures | -0.721 | -0.377 | -1.24 | -1.06 | -3.06 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.205 | — | — | -445 | 75.7 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.926 | -0.377 | -1.24 | -446 | 72.7 |
Financing Cash Flow Items | 0.065 | 0.998 | 0.716 | 1.06 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 22.5 | 340 | 3.66 | 1.98 | 1.11 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.06 | 316 | 512 | -564 | -33.6 |